GALECTIN THERAPEUTICS INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
GALECTIN THERAPEUTICS INC. (GALT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$4.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$3.61M.
- GALECTIN THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$7.69M.
- GALECTIN THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$2.10M.
- GALECTIN THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$793.00K.
- GALECTIN THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $2.60M.
- GALECTIN THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$10.54M, a 249.12% decline from fiscal 2023.
- GALECTIN THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $7.07M.
- GALECTIN THERAPEUTICS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$21.06M, a 268.37% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.45M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$3.61M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $2.60M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$3.60M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | -$1.35M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$7.69M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$10.54M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $1.40M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$62.00K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$2.10M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $7.07M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $1.77M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$626.00K 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | -$793.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$21.06M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$23.82M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$15.47M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$8.04M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $12.51M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $9.46M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $4.46M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$6.38M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$20.34M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | -$14.92M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$6.71M 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$4.15M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $39.23M 10-K · filed 2021-03-31 | |||
| 2019-09-30 | $42.08M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $43.79M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$1.28M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $5.20M 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $7.08M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |